Credit Suisse’s Editas Medicine EDIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $6.7M | Buy |
903,257
+6,781
| +0.8% | +$56.3K | 0.01% | 1139 |
|
|
2023
Q4 | $9.08M | Sell |
896,476
-245,865
| -22% | -$2.16M | 0.01% | 971 |
|
|
2023
Q3 | $8.91M | Buy |
1,142,341
+68,661
| +6% | +$589K | 0.01% | 950 |
|
|
2023
Q2 | $8.84M | Buy |
1,073,680
+95,717
| +10% | +$834K | 0.01% | 981 |
|
|
2023
Q1 | $7.09M | Sell |
977,963
-5,795
| -0.6% | -$51.5K | 0.01% | 1100 |
|
|
2022
Q4 | $8.73M | Sell |
983,758
-16,620
| -2% | -$182K | 0.01% | 988 |
|
|
2022
Q3 | $12.2M | Sell |
1,000,378
-50,195
| -5% | -$782K | 0.01% | 822 |
|
|
2022
Q2 | $12.4M | Sell |
1,050,573
-26,573
| -2% | -$356K | 0.01% | 857 |
|
|
2022
Q1 | $20.5M | Buy |
1,077,146
+6,276
| +0.6% | +$117K | 0.02% | 756 |
|
|
2021
Q4 | $28.4M | Sell |
1,070,870
-4,494
| -0.4% | -$155K | 0.02% | 915 |
|
|
2021
Q3 | $44.2M | Buy |
1,075,364
+42,024
| +4% | +$2.3M | 0.02% | 687 |
|
|
2021
Q2 | $58.5M | Buy |
1,033,340
+131,137
| +15% | +$4.84M | 0.03% | 602 |
|
|
2021
Q1 | $37.9M | Buy |
902,203
+54,224
| +6% | +$3.09M | 0.02% | 826 |
|
|
2020
Q4 | $59.5M | Sell |
847,979
-124,571
| -13% | -$5.12M | 0.03% | 631 |
|
|
2020
Q3 | $27.3M | Sell |
972,550
-45,033
| -4% | -$1.47M | 0.02% | 866 |
|
|
2020
Q2 | $30.1M | Buy |
1,017,583
+27,689
| +3% | +$724K | 0.02% | 757 |
|
|
2020
Q1 | $19.6M | Buy |
989,894
+19,642
| +2% | +$495K | 0.02% | 851 |
|
|
2019
Q4 | $28.7M | Buy |
970,252
+14,414
| +2% | +$360K | 0.02% | 833 |
|
|
2019
Q3 | $21.7M | Sell |
955,838
-32,407
| -3% | -$803K | 0.02% | 860 |
|
|
2019
Q2 | $24.4M | Buy |
988,245
+32,517
| +3% | +$776K | 0.02% | 814 |
|
|
2019
Q1 | $23.4M | Sell |
955,728
-7,522
| -0.8% | -$170K | 0.02% | 782 |
|
|
2018
Q4 | $21.9M | Buy |
963,250
+180,162
| +23% | +$4.9M | 0.02% | 754 |
|
|
2018
Q3 | $24.9M | Buy |
783,088
+227,266
| +41% | +$7.34M | 0.02% | 759 |
|
|
2018
Q2 | $19.9M | Sell |
555,822
-96,260
| -15% | -$3.41M | 0.02% | 842 |
|
|
2018
Q1 | $21.6M | Buy |
652,082
+276,794
| +74% | +$9.86M | 0.02% | 814 |
|
|
2017
Q4 | $11.5M | Buy |
375,288
+253,627
| +208% | +$6.39M | 0.01% | 1180 |
|
|
2017
Q3 | $2.92M | Sell |
121,661
-65,922
| -35% | -$1.25M | ﹤0.01% | 2222 |
|
|
2017
Q2 | $3.15M | Buy |
187,583
+33,570
| +22% | +$605K | ﹤0.01% | 1917 |
|
|
2017
Q1 | $3.44M | Sell |
154,013
-72,168
| -32% | -$1.5M | ﹤0.01% | 1927 |
|
|
2016
Q4 | $3.67M | Buy |
226,181
+140,849
| +165% | +$2.14M | ﹤0.01% | 1896 |
|
|
2016
Q3 | $1.15M | Buy |
+85,332
| New | +$1.75M | ﹤0.01% | 2838 |
|
Other funds holding EDIT
DTC
Credit Suisse's EDIT Position: Q1 2024 in Review
Credit Suisse increased its Editas Medicine (EDIT) stake by 0.76% in Q1 2024, buying an estimated $56.3K and bringing the position to 903,257 shares worth $6.7M. The position accounts for 0.01% of the portfolio, ranked #1139.
Credit Suisse first reported a position in EDIT in Q3 2016 and has held it in 31 quarters since. The position peaked at $59.5M in Q4 2020. 225 funds tracked by Wall St. Rank hold EDIT as of Q1 2024.
- Credit Suisse held 903,257 shares of Editas Medicine worth $6.7M as of Q1 2024.
- Credit Suisse bought 6,781 Editas Medicine shares in Q1 2024, an estimated $56.3K.
- Editas Medicine made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1139 holding.
- Credit Suisse first reported a position in Editas Medicine in Q3 2016 and has held it in 31 quarters since.
- Credit Suisse's Editas Medicine position peaked at $59.5M in Q4 2020.
- 225 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.